Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
Neutropenia is the most serious hematologic toxicity of cancer chemotherapy, often limiting
the doses and density of chemotherapy that can be tolerated. The degree and duration of
neutropenia determine the risk of infection. Myelo001, a small orally bioavailable molecule,
has been shown in chemotherapy- or radiotherapy-induced myelosuppression to stimulate
differentiation of peripheral white blood cells (WBC) and bone marrow cells of the
leucocytic, lymphocytic, and erythrocytic lineage. The purpose of the MyeloConcept study is
to determine the safety and effectiveness of Myelo001 in preventing or reducing
chemotherapy-induced neutropenia and myelosuppression in patients receiving chemotherapy due
to breast cancer.